Setup

Genpact (G) sits at $38.73, down 18% in a month, RSI 21, near 52-week lows. The Feb 3-4 sell-off wasn't company-specific—it was sector-wide panic. Anthropic's expanded Claude enterprise stack triggered what traders called the "SaaSpocalypse": $285B evaporated from software and IT services on fears that agentic AI would kill traditional BPO models. Indian IT giants (Infosys, TCS, Wipro) dropped 6-7% as investors priced in headcount model obsolescence.

Genpact got caught in the blast radius. The stock trades like a legacy BPO labor arbitrage play headed for disruption. 8.8x forward P/E for a company that just guided 10% EPS growth, beat-and-raised for the fifth consecutive year, and increased its dividend 10%.

The irony: Genpact isn't the victim—it's the vendor.

The Business Model Shift

Core BPO (decision support services, technology services) is still 76% of revenue and grew 3.7% in FY2025. That's the legacy business market assumes gets cannibalized. But Advanced Technology Solutions (data/AI, digital tech, agentic solutions) grew 17% to $1.2B, now 24% of total revenue, contributing more than half of total revenue growth.

Non-FTE revenue (fixed-fee, consumption-based, outcome-based contracts) hit 48% of Q4 revenue. This isn't labor arbitrage—it's software-enabled services where Genpact takes process risk and delivers outcomes, not headcount.

ATS revenue per headcount: 2x company average. 70% annuitized, 70% non-FTE model. These are high-quality, sticky contracts.

AgenTeq: The Fastest Product Launch in Company History

From the Q4 2025 earnings call (verified in transcript):

"Last February, launched AP Capture, first module accounts payable agentic suite... closed over $200 million total contract value AP agentic solutions. Over 40% awarded contract value came new clients. Existing accounts FTE-led AgenTeq, both gross margin expansion notably above what Investor Day last June."

$200M+ TCV in under a year. CEO Kalra: "Not seen takeoff solution Genpact history [at this] pace."

40% of AgenTeq bookings came from net new clients—companies that never used Genpact before. Existing clients rotating from FTE-led AP to AgenTeq are seeing revenue growth and margin expansion above June 2024 targets.

Case study from the call: Vesco (Fortune 500 distribution/logistics) transitioned entire AP operation to agentic automation. Touchless invoice processing improved from 40% to 65% on 3M invoices annually. HFS Research called it "evidence payable no longer back-office function... becoming frontline enterprise AI."

ISG named Genpact a Leader in its Dec 2025 Provider Lens for GenAI/Agentic AI Services in Insurance (verified via Seeking Alpha sourcing). The firm is building domain-specific agentic suites (AP, insurance underwriting/claims) on proprietary process data from running Fortune 500 operations for decades.

The Mis-Categorization Trade

Market is treating G as if it's TaskUs (TASK): down 32% 1Y, 8.6% short interest, pure-play BPO exposed to AI displacement with no offsetting product revenue.

Reality: G is closer to Accenture (ACN) in business model—selling AI transformation services—but trading at 8.8x forward P/E vs ACN's 19.6x.

G has lower beta and higher idio variance than ACN, meaning the recent move is disproportionately sector-driven. The Feb 3-4 collapse in Indian IT services (consensus trade: "AI kills BPO") dragged G down despite fundamentally different exposure.

What Worldview Already Knows

We've been building the quality compression framework for months:

• Evidence on TaskUs (TASK): "BPO industry slowed as clients reduce costs via GenAI" (CEO admission, LR 0.6 bearish)
• Evidence on RHI (staffing): Down 58% 1Y as temp roles compress
• Evidence on beneficiaries: Intapp (INTA), Doximity (DOCS)—tools for fewer, better professionals

G is the missing piece: the company SELLING the compression.

From accumulated evidence:

"The investable angle is LONG quality-compression beneficiaries (tools for fewer/better workers) and SHORT quality-compression victims (temp staffing, commodity BPO, per-head SaaS)."

G got sold as a victim when it's actually a beneficiary—and not just passively benefiting, but actively driving the transition by selling the agentic tools enterprises use to compress headcount.

The Numbers

FY2025:

• Revenue: $5.08B (+6.6%)
• Adj EPS: $3.65 (+11.3%, fifth consecutive year EPS growth > revenue growth)
• Gross margin: 36.0% (+60bps YoY)
• Adj OI margin: 17.5% (+40bps)
• Operating cash flow: $813M (including $170M client prepayments; $643M ex-prepayments, +5% YoY)
• Share buybacks: $283M at avg $46.16/share (stock now $38.73)

FY2026 Guidance:

• Revenue: "at least 7%" growth
• ATS: "at least high teens" growth (on top of 17% in FY2025)
• Gross margin: 36.5% (+50bps)
• Adj OI margin: 17.7% (+25bps)
• Adj EPS: ≈10% growth
• Committed revenue: 75% of guide (historical average, backed by record backlog)
• Dividend: $0.75/share annual (+10%)

Valuation:

• Market cap: $6.8B
• Forward P/E: 8.8x (for 10% EPS growth)
• Analyst targets: $42-58 (mean $50.09, +29% upside)
• Consensus: Neutral (42% bullish, 0% bearish—no sell ratings)

Four consecutive quarters of earnings beats. Beat-and-raise in Q4 (EPS $0.97 vs $0.93 est). Stock down 18% in a month anyway.

Risk: The Cannibalization Question

Core BPO is still 76% of revenue. If agentic AI cannibalizes traditional outsourcing faster than Genpact can replace it with ATS revenue, the bull case breaks.

Current trajectory:

• Core grew 3.7% in FY2025 (not shrinking)
• ATS grew 17% and is accelerating to "at least high teens" in FY2026
• Existing clients rotating FTE→AgenTeq are seeing revenue and margin expansion, not compression

Management's view (CFO Weiner, Q4 call): Core business "accelerate AI-led transformations agentic operations" as clients realize "last-mile advantage" of Genpact running mission-critical ops at scale.

The risk is priced like certainty (stock at 52-week lows, 8.8x P/E) when it's actually uncertain. If the business model shift works—ATS keeps growing high-teens, core stabilizes or grows modestly, margins expand—the current valuation is absurd.

What's Missing

Factor decomposition: How much of the -18% move is sector beta vs company-specific? If G is >70% driven by sector (Indian IT services panic) and the idiosyncratic story is differentiating (AgenTeq traction, non-FTE model shift), the rebound trade is compelling.

Competitive moat validation: Is AgenTeq actually differentiated vs Accenture/Infosys AI offerings, or just rebranded consulting? The $200M TCV, 40% from new clients, and Vesco case study suggest real product-market fit. But need to verify: Are clients buying because of Genpact's process data (proprietary) or just because it's cheaper than building in-house (commoditized)?

ATS growth sustainability: $1.2B growing at high-teens is impressive, but is the adoption curve steepening (early innings) or plateauing (pull-forward)? Management says pipeline "never higher" and ATS bookings now ">1/3 of total bookings." That points to steepening, not saturation.

Thesis

Genpact is being sold as a BPO victim at a valuation extreme (RSI 21, 8.8x fwd P/E, 52-week lows) despite being an AI solution vendor—the company selling the tools that kill traditional BPO.

This is the long side of the quality-compression trade we've been building the short side of (TASK, RHI). The sector sell-off (Feb 3-4 SaaSpocalypse) created a mis-categorization opportunity: market lumped G in with Indian IT services getting disrupted when G's business model is fundamentally different (48% non-FTE revenue, ATS growing 17%+, margin expanding).

The setup: Asymmetric payoff if market re-categorizes G from "BPO victim" to "AI services vendor." Beat-and-raise guidance, record backlog, 75% committed revenue, double-digit EPS growth—none of that justifies 8.8x P/E unless you believe core BPO collapses faster than ATS replaces it.

What makes this interesting: G isn't just passively benefiting from quality compression—it's driving it. Enterprises use AgenTeq to compress their own headcount, which validates the secular trend and gives Genpact the contract (revenue + margin expansion). The faster AI adoption accelerates, the more enterprises need partners who've already run their processes at scale and can embed agentic solutions into existing workflows.

The trade: Long at RSI 21 / 8.8x fwd P/E with 10% EPS growth guided. Catalyst timeline: Q1 2026 earnings (late April/early May) will show whether ATS is still accelerating. If guidance holds and ATS prints high-teens growth, multiple re-rating is likely.

Conviction: Can't size without factor decomposition (need to know how much is sector beta vs idio). But if >70% of recent move is sector-driven, this is a quality dislocation at a valuation extreme.